GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Seres Therapeutics
Seres Therapeutics is a pioneer in microbial therapeutics. Its stock price reflects its breakthrough in creating the first FDA-approved microbiome-based drug. The chart is a story of scientific innovation and the long road to commercialization of an entirely new class of drugs.
Share prices of companies in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, developing bacterial-based drugs for the treatment of infectious and inflammatory diseases. We classify it as "Pharmaceuticals (Infections)," where it is pioneering a completely new approach to treatment. The graph below illustrates the dynamics of this innovative and breakthrough sector.
Broad Market Index - GURU.Markets
Seres Therapeutics is a pioneer in microbiome therapy, developing drugs based on live bacteria for the treatment of infectious and inflammatory diseases. As a component of the GURU.Markets index, it is at the forefront of science. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MCRB - Daily change in the company's share price Seres Therapeutics
Shares of Seres, a microbiome therapy company, exhibit high volatility, as measured by change_co. This reflects the company's sensitivity to the commercial success of its first approved drug. This metric is important for analyzing the innovative biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma infections
Seres Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with MCRB, a pioneer in microbiome therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Seres Therapeutics is a pioneer in developing drugs based on the gut microbiome. This is a new and revolutionary field of medicine. The company's shares are highly volatile and depend on research advances, contributing to the overall market dynamics shown in the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Seres Therapeutics
Seres Therapeutics' year-over-year performance is a story of creating a new class of microbiome-based drugs. Its market cap growth over the past 12 months reflects the successful approval and launch of its first drug for the treatment of C. difficile infection, which is a fundamental validation of its scientific platform and ushers in a new era in medicine.
Annual dynamics of market capitalization of the market segment - Pharma infections
Seres Therapeutics, Inc. is a pioneer in microbial therapeutics. Its first approved drug was a breakthrough in the treatment of recurrent infections. This chart shows how the market perceives the commercial potential of its unique platform and its progression from development to commercialization.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Seres, a pioneer in microbial therapy, is a high-risk, high-potential company. Its stock price is entirely dependent on the success of its drugs. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become the new standard in infectious disease treatment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy. Its market capitalization is extremely sensitive to news from the worlds of science and medicine. The monthly dynamics on the chart are essentially a chronicle of its clinical trials: positive trial data or FDA approval trigger explosive growth, while failures or delays lead to sharp declines.
Monthly dynamics of market capitalization of the market segment - Pharma infections
This graph reflects the dynamics of the cutting-edge biotech sector focused on the microbiome. For Seres, a pioneer in this field, it's the backdrop. Its movements demonstrate how successes in clinical trials and FDA approvals can create powerful trends for this entire emerging niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Seres Therapeutics is a pioneer in microbial therapeutics and the first company to receive FDA approval for a microbiome-based drug. This full-market chart allows you to assess how Seres' shares are performing after transitioning from risky development to commercial growth, and how its unique product allows it to defy overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Seres Therapeutics
Seres Therapeutics is a pioneer in microbial therapy, the first company to receive FDA approval for a microbiome-based drug. Its weekly stock price is driven by the successful launch of this product and news about clinical trials of other candidates.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based drug development, a new and promising area of medicine. The company's shares are driven by news of research and regulatory approvals. The chart will show how its unique scientific foundation is driving its own investment trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Seres is a pioneer in microbiome-based therapies. The company's shares are driven by research news and regulatory decisions. The chart will show how its unique scientific foundation creates its own investment trend, unrelated to the market.
Market capitalization of the company, segment and market as a whole
MCRB - Market capitalization of the company Seres Therapeutics
Seres Therapeutics' market capitalization is the story of a pioneer in microbiome therapy. Its volatile price chart reflects both its first-ever success—the approval of its drug for the treatment of C. difficile—and the challenges associated with commercialization and the development of other drugs based on "good" bacteria.
MCRB - Share of the company's market capitalization Seres Therapeutics within the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, developing drugs based on live bacteria. Its market share reflects both the first-ever approved drug in this field and the potential of the entire platform. The chart tells the story of the creation of an entirely new class of drugs.
Market capitalization of the market segment - Pharma infections
Here's a chart showing the market capitalization of the biotech sector. Seres Therapeutics is a pioneer in microbiome therapy, developing drugs based on "good" bacteria. The growth of this market you're seeing reflects a revolution in our understanding of the role of the microbiome. Seres is at the forefront of this emerging field of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Seres Therapeutics is a pioneer in the development of microbial therapeutics that utilize beneficial bacteria to treat diseases. Its market capitalization is a bet on microbiome medicine. The chart below shows the economic impact of this emerging scientific field.
Book value capitalization of the company, segment and market as a whole
MCRB - Book value capitalization of the company Seres Therapeutics
Seres Therapeutics' foundation is its scientific platform for developing microbiome-based drugs. This chart tells the story of a pioneer in this field, which, after receiving approval for its first drug (VOWST), begins to turn years of R&D investment into commercial assets, radically changing its balance sheet.
MCRB - Share of the company's book capitalization Seres Therapeutics within the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy. The chart shows its share of actual R&D and manufacturing assets. These include its laboratories and unique facilities for producing live bacteria-based medications that restore intestinal balance.
Market segment balance sheet capitalization - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy. Its value lies in scientific discoveries, not manufacturing. The chart below reflects the capital intensity of the pharmaceutical sector, demonstrating how lightweight its business model is.
Book value of all companies included in the broad market index - GURU.Markets
Seres Therapeutics is a pioneer in microbiome therapy. The company's assets include its manufacturing facilities for creating bacterial-based medications. Its stake in BCap_All provides the material basis for an entirely new class of drugs that treat diseases by restoring microbiome balance.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Seres Therapeutics
Seres Therapeutics' book value is its labs and capital. But the market sees more than that; it sees a revolution in medicine. Seres is a pioneer in microbiome-based therapies, and its enormous market premium is the valuation of Vowst, the first-ever FDA-approved oral bacteria-based drug. The chart shows the price investors are paying for the creation of a new class of drugs and a scientific platform that promises new breakthroughs.
Market to book capitalization ratio in a market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy. Its valuation is based on its scientific platform and the first approved drug in this field. The chart shows the premium investors are paying for its leadership in an entirely new class of drugs.
Market to book capitalization ratio for the market as a whole
Seres Therapeutics is a pioneer in microbiome therapy. The company develops drugs based on live bacteria. Its entire value lies in its cutting-edge scientific platform. This chart shows the extreme premium investors are willing to pay for this potentially revolutionary technology, ignoring traditional assets.
Debts of the company, segment and market as a whole
MCRB - Company debts Seres Therapeutics
Seres Therapeutics, a pioneer in microbial therapeutics, is using capital to commercialize its first-of-its-kind products. Its debt burden reflects the costs of bringing its C. difficile treatment to market, as well as research into applying its platform to other diseases, which requires significant investment.
Market segment debts - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapeutics, using beneficial bacteria to treat diseases. This is a completely new field of medicine that requires massive investment in research. This chart shows how the company funds its breakthrough, yet expensive, clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome-based drug development. Commercializing this innovative approach requires significant investment in clinical trials and manufacturing. This chart illustrates the company's reliance on debt to bring its first products to market, a key risk factor.
Market segment debt to market segment book capitalization - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, having developed the first FDA-approved microbiota-based drug. This chart shows debt trends in their sector. It helps assess how the company is funding the commercialization of its revolutionary product and further research in this emerging field of medicine, and how this impacts its financial profile.
Debt to book value of all companies in the market
Seres Therapeutics is a pioneer in microbiome therapy. After years of research, the company received approval for its first product. This transition from R&D to commercialization is changing its financial profile. This chart helps assess whether Seres is beginning to use debt financing to bring its product to market, as mature pharmaceutical companies do, or whether it still relies on shareholders.
P/E of the company, segment and market as a whole
P/E - Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs to treat diseases. This chart shows how investors view its revolutionary approach. This valuation is based on the success of its first approved drug and the potential of its entire platform to treat a variety of diseases.
P/E of the market segment - Pharma infections
This chart for biotech companies serves as a benchmark for Seres Therapeutics. It reflects the overall sentiment in the sector. Comparisons with it help understand how the market views Seres' leadership in the emerging field of microbiome-based therapies, which offers enormous potential but also carries significant risks associated with the novelty of this scientific field.
P/E of the market as a whole
Seres Therapeutics is a pioneer in developing microbiome-based drugs for the treatment of infectious and inflammatory diseases. The company's valuation represents a bet on a new field of medicine. This chart of overall biotech risk appetite shows whether investors are willing to fund research in this revolutionary, yet still underexplored, field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs for the treatment of infectious and inflammatory diseases. This timeline reflects expectations for this new class of drugs. The valuation is contingent on the commercial success of its first approved drug and progress in developing other candidates for restoring a healthy microbiome.
%20P%2FE%20Seres%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Seres-Therapeutics&v=1772513784004 "Chart of the company's future (projected) P/E Seres Therapeutics")
Future (projected) P/E of the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs to treat diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's confidence in its innovative approach and potential to create a new class of drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772513784005 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Seres Therapeutics is a pioneer in developing microbiome-based drugs for the treatment of infectious and inflammatory diseases. For a company working in a new field of medicine, this market risk appetite curve is vital. Funding for their innovative research is directly dependent on investors' willingness to invest in long-term, high-risk projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513784013 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome-based therapeutics. The company develops drugs containing live bacteria to treat conditions associated with intestinal flora imbalances. This chart shows the financial results of the company, which is at the forefront of this new field of medicine.
Profit of companies in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based drug development. This chart shows the profitability of the pharmaceutical sector. For MCRB, this reflects a scientific breakthrough in understanding the role of gut bacteria in human health. Their first approved drug has opened a new era in medicine, and the market is appreciating the potential of this platform.
Overall market profit
Seres Therapeutics is a pioneer in microbiome-based drug development. Its first drug has been approved for preventing recurrence of Clostridioides difficile infection. This is a new area of medicine with great potential. The company's success depends on further research. This timeline does not reflect the future prospects of this innovative scientific field.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome-based therapeutics. The revenue forecast presented here depends on the commercial success of its first approved drug, VOWST, for preventing recurrence of C. difficile infection, and the success of its other developments in clinical trials.
%20profit%20of%20the%20company%20Seres%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Seres-Therapeutics&v=1772513784037 "Graph of future (projected) profit of the company Seres Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapeutics, developing drugs to treat infections and inflammatory diseases. The profit forecast for this emerging sector hinges on the success of this revolutionary approach. This chart reflects analysts' belief that managing the gut microbiome will become a crucial part of the future of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772513784040 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Seres Therapeutics is a pioneer in developing microbiome-based drugs for the treatment of infectious and inflammatory diseases. The company's success depends on the approval of its innovative drugs. The market revenue forecasts shown here reflect the overall investment climate for leading biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513784042 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome-based drug development. This chart shows how the market values its revenue following the approval of the first drug in its class. This value reflects both the potential of its scientific platform for treating various diseases and the commercial risks associated with launching a new product.
P/S market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, developing drugs based on live bacteria for the treatment of infectious and inflammatory diseases. This is a new and promising area of medicine. This chart shows the average revenue estimate in the biotech sector, which helps us understand the premium the market is paying for Seres' innovative platform.
P/S of the market as a whole
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs for the treatment of infectious and inflammatory diseases. The company has already launched the first-ever approved drug of this type. This chart provides a market-wide perspective on investor sentiment for this entirely new class of drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy, developing drugs based on live bacteria for the treatment of infectious and inflammatory diseases. This chart shows how investors estimate the company's future revenue, reflecting the potential of this new class of drugs.
%20P%2FS%20Seres%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Seres-Therapeutics&v=1772513784054 "The graph of the company's future (projected) P/S Seres Therapeutics")
Future (projected) P/S of the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs to treat diseases. Its first drug was approved to prevent recurrence of C. difficile infection. This chart reflects investors' faith in its groundbreaking science and the potential of the microbiome as a new class of medicine.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772513784057 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Seres Therapeutics is a pioneer in microbiome therapy, developing bacteria-based drugs to treat diseases. This is a new and risky field. This market optimism chart is important for MCRB. Funding breakthrough but under-researched areas of medicine is only possible with a high investor appetite for risk and faith in scientific progress.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513784059 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Seres Therapeutics
Seres Therapeutics is a pioneer in a new field of medicine—microbiome-based treatments. The company has received approval for the world's first oral microbiome-based drug for the treatment of C. difficile infection. This chart shows initial sales revenue. Revenue growth will reflect the medical community's acceptance of this revolutionary approach.
Sales of companies in the market segment - Pharma infections
Seres Therapeutics is a pioneer in a new field of medicine—microbiome-based therapies. Their first approved drug, VOWST, is designed to prevent recurrence of C. difficile infection by restoring a healthy gut microbiome. Their early-stage revenue is generated by sales of this revolutionary product.
Overall market sales
Seres Therapeutics is a pioneer in microbiome-based drug development. The company creates drugs containing live bacteria to treat infectious and inflammatory diseases by restoring a healthy balance in the gut. This revenue chart includes the healthcare sector, where MCRB is pioneering a new direction in medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy. The company develops treatments based on live bacteria to treat diseases associated with intestinal microbiome imbalances. This timeline reflects expectations for the commercialization of its first approved drug and the success of its other programs.
%20sales%20of%20the%20company%20Seres%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Seres-Therapeutics&v=1772513784065 "Schedule of future (projected) sales of the company Seres Therapeutics")
Future (projected) sales of companies in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapeutics, developing drugs from live bacteria to treat infectious and inflammatory diseases. This chart shows forecasts for the emerging microbiome therapy market. It reflects expectations for the development of this new class of drugs, which has the potential to revolutionize the treatment of many diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772513784067 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Seres Therapeutics, a pioneer in microbiome therapy, sees this chart as a reflection of the market's readiness for innovation. The stable economic growth predicted here allows healthcare systems to implement fundamentally new treatment approaches. Seres's products utilize beneficial bacteria to fight infections.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513784068 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Seres Therapeutics
Seres Therapeutics is a pioneer in developing microbiome-based drugs for the treatment of infectious and other diseases. The company's profitability depends on the success of its innovative drugs. This chart shows the balance between revenue from its first approved product and ongoing investment in research into other therapeutic candidates.
Market segment marginality - Pharma infections
Seres Therapeutics is a pioneer in the development of microbiome-based therapeutics for the treatment of infectious and inflammatory diseases. This indicator reflects the commercial success of its innovative approach. This high result demonstrates the recognition of its products and the creation of an entirely new class of drugs.
Market marginality as a whole
Seres Therapeutics is a pioneer in microbiome-based drug development. It's a clinical-stage company whose value is based on the potential of its innovative scientific platform. This gross profitability chart bears no relation to the world of advanced biotechnology, where risks and opportunities are determined by science.
Employees in the company, segment and market as a whole
Number of employees in the company Seres Therapeutics
Seres Therapeutics is a pioneer in microbial therapeutics. The company develops drugs based on live bacteria to treat diseases associated with disruption of the gut microbiome. This graphic shows a team of scientists working on a new class of drugs to combat infections such as Clostridium difficile.
Share of the company's employees Seres Therapeutics within the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapeutics, developing drugs to treat infectious and inflammatory diseases. This completely new field of medicine requires a team of exceptional microbiologists. This graph shows the concentration of scientific talent needed to become a leader in this revolutionary field.
Number of employees in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy. The company develops treatments based on live bacteria to treat diseases associated with intestinal microflora imbalances. This graphic shows a team of microbiologists working at the forefront of science, using bacteria to treat serious infections and inflammatory diseases.
Number of employees in the market as a whole
Seres Therapeutics is a pioneer in microbiome-based therapies for infectious diseases. Their innovative work requires significant investment. The overall economic environment, reflected in the employment chart, provides the backdrop for such funding. A stable market attracts capital to cutting-edge biotech, allowing Seres to bring new classes of drugs to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Seres Therapeutics (MCRB)
Seres Therapeutics is a pioneer in microbiome-based therapies. This chart represents a revolutionary approach to medicine. Their very high market capitalization reflects the market's belief that their drugs, which restore the balance of gut bacteria, will become a new class of treatment for a wide range of diseases.
%20of%20the%20company%20Seres%20Therapeutics%20(MCRB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Seres-Therapeutics-MCRB&v=1772513784090 "Chart of market capitalization per employee (in thousands of dollars) of the company Seres Therapeutics (MCRB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapies for infectious and other diseases. Its value is based on its innovative scientific platform. This chart shows how the market values its cutting-edge research and commercialization potential per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772513784094 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Seres Therapeutics is a pioneer in developing microbiome-based drugs for the treatment of infectious and inflammatory diseases. This statistic reflects the revolutionary nature of its approach. The high valuation per employee reflects investors' belief that regulating gut microbiota could become a new class of therapy.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513784108 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Seres Therapeutics (MCRB)
Seres Therapeutics is a pioneer in microbiome therapy. Their first drug for C. diff (VOWST) has been approved. This timeline shows the start of commercialization. After decades of R&D, their team (in partnership with Nestlé) is launching the product commercially. Its effectiveness will increase as sales grow.
%20Chart%20Seres%20Therapeutics%20(MCRB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Seres-Therapeutics-MCRB&v=1772513784121 "Company Profit Per Employee (in thousands of dollars) Chart Seres Therapeutics (MCRB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Seres Therapeutics (MCRB) is a pioneer in microbiome therapy. They develop bacteria-based drugs (including the already approved Vowst) to treat infections (like C. diff) and inflammatory diseases. This chart represents an industry benchmark. It reflects how successfully Seres is commercializing this entirely new class of drugs, managing complex manufacturing and training physicians.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772513784144 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Seres Therapeutics (MCRB) is a pioneer in microbiome-based therapeutics. Their first product (VOWST) is an oral therapy (tablets) for C. difficile, based on bacterial spores. This represents a combination of R&D and commercialization. This chart shows the balance between R&D costs per scientist and the effectiveness of their sales team bringing this unique product to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513784149 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Seres Therapeutics (MCRB)
Seres Therapeutics is a pioneer in microbiome-based therapeutics. This chart shows the commercialization trajectory of an entirely new class of drugs. The growth in revenue per employee reflects sales of its first approved drug for C. difficile infection and demonstrates the potential of this innovative approach for treating other diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Seres-Therapeutics-MCRB&v=1772513784170 "Sales chart per company employee Seres Therapeutics (MCRB)")
Sales per employee in the market segment - Pharma infections
Seres Therapeutics (MCRB) is a pioneer in microbiome-based therapeutics. They received approval for the world's first oral drug (Vowst). This graph shows how the company progresses from R&D (large staff, no revenue) to commercialization (initial sales) compared to the industry average.
Sales per employee for the market as a whole
Seres Therapeutics is a pioneer in microbiome therapy. They created the world's first oral (capsule-based) drug (Vowst) that uses "good" bacteria to treat C. diff. This chart shows how their R&D and commercial teams are beginning to generate revenue from this innovative product.
Short shares by company, segment and market as a whole
Shares shorted by company Seres Therapeutics (MCRB)
Seres Therapeutics (MCRB) is a biotech company pioneering microbiome-based therapeutics. They developed the first FDA-approved drug (Vowst) for the treatment of C. difficile. This chart measures bearish bets. The rise in shorts may reflect investor doubts about the commercial success of Vowst or skepticism about the rest of their microbiome platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Seres-Therapeutics-MCRB&v=1772513784185 "Short Shares Chart for the Company Seres Therapeutics (MCRB)")
Shares shorted by market segment - Pharma infections
Seres (MCRB) is a biotech company pioneering microbiome-based therapies for treating infections such as C. difficile. This chart illustrates the general skepticism in the biotech sector, reflecting investor doubts about the commercial success of this new class of drugs.
Shares shorted by the overall market
Seres Therapeutics (MCRB) is a pioneer in microbiome-based therapeutics. This cutting-edge science is still unprofitable. When this market fear indicator rises, investors are unwilling to fund R&D. They are selling off biotech companies en masse without profits, fearing that MCRB will be unable to attract capital to bring its products to market in the current panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Seres Therapeutics (MCRB)
Seres Therapeutics (MCRB) is a pioneer in treating diseases through the "microbiome" (gut bacteria). They received approval for the world's first fecal "drug," Vowst. This chart measures how investors are viewing this launch. It shows when the stock is "overbought" due to hype or "oversold" due to slow selling.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Seres-Therapeutics-MCRB&v=1772513784205 "RSI 14 indicator chart for the company's stock Seres Therapeutics (MCRB)")
RSI 14 Market Segment - Pharma infections
Seres Therapeutics is a pioneer in microbiome-based therapeutics. They were the first in the world to receive FDA approval for their oral treatment, Vowst (based on live bacteria), to prevent C. diff recurrence. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this innovative field.
RSI 14 for the overall market
Seres (MCRB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MCRB (Seres Therapeutics)
Seres Therapeutics (MCRB) is a biotech company pioneering microbiome-based therapies. This chart shows the average 12-month forecast. It reflects analyst expectations for the commercial launch of its first approved drug (VOWST) and the potential of other developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MCRB-Seres-Therapeutics&v=1772513784234 "A chart showing analyst consensus forecasts for the expected stock price. MCRB (Seres Therapeutics)")
The difference between the consensus estimate and the actual stock price MCRB (Seres Therapeutics)
Seres Therapeutics is a pioneer in the microbiome field. The company developed Vowst, the world's first live bacteria-based oral therapy for preventing C. Difficile recurrence. This chart shows analysts' forecasts for the stock's upside and downside. It measures the gap between the price and forecast, reflecting their confidence in the launch of this new class of drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MCRB-Seres-Therapeutics&v=1772513784258 "A chart showing the difference between the consensus forecast and the actual stock price. MCRB (Seres Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Seres Therapeutics (MCRB) is a pioneer in the field of "microbiome" therapeutics. The company developed Vowst, the first oral (capsule) bacterial-based therapy for the treatment of C. diff. This chart shows general expectations for the pharmaceutical sector, reflecting whether experts believe in the commercial success of "good bacteria" treatments.
Analysts' consensus forecast for the overall market share price
Seres Therapeutics (MCRB) is a pioneer in microbiome-based treatments. They developed the first oral (pill) therapy based on "good" bacteria for the treatment of severe intestinal infections (C. Diff). This chart shows overall market sentiment. For Seres, which is bringing a new class of drugs to market, how risk appetite (sentiment) influences their commercialization is important. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Seres Therapeutics
Seres Therapeutics is a pioneer in microbiome therapy. Their flagship product, VOWST, is the world's first oral (capsule-based) live bacteria therapy approved by the FDA for the prevention of recurrent C. difficile infection. This chart evaluates their commercial launch, measuring their success in convincing physicians and patients to adopt this revolutionary new class of live medications.
AKIMA Market Segment Index - Pharma infections
Seres Therapeutics is a pioneer in microbiome therapy. Its first drug, VOWST (for the treatment of C. difficile), became the first FDA-approved oral microbiome drug. This chart shows the industry average. It allows you to assess how Seres' innovative approach to microbiome-based treatment compares to the industry average.
The AKIM Index for the overall market
Seres Therapeutics is a pioneer in microbiome therapy and developed the first FDA-approved oral microbiome drug (Vowst). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which sold the rights to its flagship product to Nestlé, compares to overall economic trends.
